Sernova

*New Data to be Presented* Sernova announces today, that Dr. Piotr Witkowski MD PhD, Professor of Surgery, and Director of the Pancreatic and Islet Transplant Program, and his islet transplant team at University of Chicago Medicine, authored an abstract that will be presented, including new data from the ongoing Phase I/II clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D). . This presentation will be held at the European Association for the Study of Diabetes (EASD) on September 12, 2024, in Madrid, Spain. Read our full press release here: https://lnkd.in/g3pRviza

Today we announced the appointment of Jonathan Rigby, Executive Chairman of our Board of Directors, as our Chief Executive Officer. With 30+ years of #biopharma industry experience, he will lead the team as we develop regenerative medicine cell therapies for chronic diseases including #T1D. Learn more by reading our press release: https://bit.ly/4dew24K

An exciting and heart-warming testimonial from the first patient enrolled in our Phase I/II clinical trial. As we progress through our clinical study, we’re committed to providing a “functional cure”, via our Cell Pouch System™️ for all patients affected by T1D and other applicable chronic conditions❤️

Breakthroughs in Type 1 Diabetes Research | Sernova | Airing on BNN Bloomberg Sernova is making significant strides in the treatment of type 1 diabetes with its cutting-edge clinical trials. Their groundbreaking approach has led to multiple patients achieving insulin independence and maintaining long-term blood sugar control within the non-diabetic range. This promising development could mark a major advancement in diabetes management, offering hope to millions affected by the condition. As Sernova continues its research, the future looks bright for those seeking more effective diabetes treatments. (TSX: SVA, OTCQB: SEOVF) Learn More: https://lnkd.in/eMT6FwZE #Diabetes #DiabetesTreatment #BloodSugarControl #ClinicalTrials #HealthcareStocks #StocksinFocus #StockstoWatch

As seen on BNN Bloomberg “Sernova’s promising results in its innovative clinical trials, mark a major advancement…offering hope to millions affected by the condition.” The future is exciting. The future is Sernova ❤️🩹 Sernova is listed on the TSX: SVA, OTCQB: SEOVF and FSE/XETRA: PSH.

Sernova’s vision, is a future where chronic conditions are no longer insurmountable obstacles. Learn more at Sernova.com

FOR IMMEDIATE RELEASE: Jonathan Rigby Appointed as Executive Chairman for Sernova “I am delighted to serve Sernova & its shareholders as Executive Chairman with passion and enthusiasm. As a sufferer myself, I will do all I can to help Sernova give lives back to patients suffering from diseases such as Type 1 Diabetes. I have financed and grown multiple companies through to exits and my goal is quite clear, I will work tirelessly with the team to do the same for Sernova and its shareholders.” - Jonathan Rigby Read Full Press Release here: https://lnkd.in/ekcNEaUn

Sernova is committed to advancing the development of our Hemophilia A program and has shown success in pre-clinical models.

Sernova Announces Clinical Update!